Chin BumSik, Kim Yeonjae, Kim Gayeon, Jeon Jaehyun, Kim Min-Kyung, Jeong Jae Yoon, Kwon Hyeokchoon, Nam Seongwoo
Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Infect Chemother. 2024 Dec;56(4):544-550. doi: 10.3947/ic.2024.0133.
Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can cause more rapid progression to cirrhosis than HCV-monoinfection. In this study, incident HCV case (IHCV)s were investigated in a HIV clinic in Korea.
A retrospective HIV cohort was constructed who visited National Medical Center in Korea from 2013 to 2022 and performed ≥ 1 anti-HCV antibody tests (anti-HCV) during the study period. IHCV was defined as newly confirmed HCV infection by PCR with a prior negative anti-HCV and factors associated with IHCV were investigated among alanine aminotransferase (ALT) >150 IU/mL sub-cohort without plausible reasons for ALT elevation.
Overall, 2,567 HIV clinic visitors were recruited during the study period and 42 (1.63%) were confirmed as HIV/HCV co-infection. Fifteen IHCVs were identified during the study period. While no IHCV was observed in 2013-2015, incidence of 2016-2019 and 2020-2022 were 0.84 and 1.48 per 1000 person-year, respectively. Subtype 1a were more common among IHCVs in 2020-2022 (8/9) while subtype 2 dominated in 2016-2019 (5/6, =0.003). Most IHCVs were identified during the evaluation of de novo liver enzyme elevation which was identified through the regularly performed blood tests (86.7%, 13/15). Comparing twelve IHCVs with ALT>150 IU/mL with 58 HIV mono-infection comparators whose peak ALT exceeded 150 IU/mL during the study period, age, sex, HIV/HCV infection risk factor, CD4 cell count, and HIV-RNA viral load were not different between two groups. However, mean peak ALT of IHCVs was higher than comparators (776 237, <0.001) and syphilis treatment within prior 24 months of ALT elevation was more common in IHCV group (41.7% 12.7%, =0.026).
Incidence rate of HCV among PLH revealed increasing trend between 2013 and 2022 among visitors at a HIV clinic in Korea. Subtype 1a dominated among IHCVs after 2020 and recent syphilis treatment was associated with IHCVs.
人类免疫缺陷病毒(HIV)与丙型肝炎病毒(HCV)合并感染比单纯HCV感染可导致更快速地发展为肝硬化。在本研究中,对韩国一家HIV诊所的新发HCV病例(IHCV)进行了调查。
构建了一个回顾性HIV队列,该队列中的患者在2013年至2022年期间就诊于韩国国立医疗中心,并在研究期间进行了≥1次抗-HCV抗体检测(抗-HCV)。IHCV被定义为通过PCR新确诊的HCV感染,且之前抗-HCV为阴性,并在丙氨酸氨基转移酶(ALT)>150 IU/mL的亚组中调查了与IHCV相关的因素,该亚组中ALT升高无合理原因。
总体而言,在研究期间招募了2567名HIV诊所就诊者,其中42例(1.63%)被确诊为HIV/HCV合并感染。在研究期间共识别出15例IHCV。2013 - 2015年未观察到IHCV,2016 - 2019年和2020 - 2022年的发病率分别为每1000人年0.84例和1.48例。2020 - 2022年期间,1a亚型在IHCV中更为常见(8/9),而2016 - 2019年期间2型占主导(5/6,P = 0.003)。大多数IHCV是在对通过定期血液检测发现的新发肝酶升高进行评估时被识别出来的(86.7%,13/15)。将12例ALT>150 IU/mL的IHCV与58例HIV单感染对照者进行比较,这些对照者在研究期间ALT峰值超过150 IU/mL,两组在年龄、性别、HIV/HCV感染危险因素、CD4细胞计数和HIV - RNA病毒载量方面无差异。然而,IHCV的平均ALT峰值高于对照者(776±237,P<0.001),且在ALT升高前24个月内接受梅毒治疗在IHCV组中更为常见(41.7%对12.7%,P = 0.026)。
在韩国一家HIV诊所的就诊者中,2013年至2022年期间PLH中HCV的发病率呈上升趋势。2020年后1a亚型在IHCV中占主导,近期梅毒治疗与IHCV有关。